Close

Share this page

Australia

Thanks to a favorable tax climate, efficient regulatory policies and world-class research sector for phase I, phase II and phase III activities, EPSI has had a solid presence in Australia since 2006. The popularity of Australia as a destination for clinical trials has exploded in the 21st century. Since 2003 there has been a 10-fold increase in the number of trials (2016 figures). The country's cutting-edge clinical trial diagnostics and advanced monitoring facilities make it ideal for clinical research, especially in the field of oncology.


Fast Facts

Health Expenditure per Capita
(2014, US$)

$6031

Source: World Health Organization Global Health Expenditure Database

Life Expectancy at Birth
(2016 est.)

male

79

years

female

84

years

Source: The World Fact Book;
Central Intelligence Agency

Burden of Disease DALYs Causes % of Total DALYs
(2015, all ages/both sexes)

Low back and neck pain (7.73%)

Ischemic heart disease (6.9%)

Depression (4.38%)

Source: Global Burden of Disease Study 2015;
Institute for Health Metrics and Evaluation

NDA Approval Time

7

months



11

months




Features

Phase 1 clinical trial opportunities: Australia shows the world it's open for business

Clinical trial opportunities are booming in Australia as companies around the world look for new ways to secure reliable data and get ahead of their competitors. Australia is growing rapidly as a research centre, with 1,700 new clinical trials ...

For global cancer clinical trials, Australia is a premium location

Cancer Australia, an Australian government agency, estimated new cancer cases diagnosed in 2016 at 130,466. Cancer Australia also estimated the number of deaths from cancer in 2016 at 46,880 ...


Services Available in Australia

Homebase c/o Singapore Office

150 Beach Road, #06-03/04 The Gateway West, Singapore
E-mail: info@epsi-global.com


We will tailor an ideal solution for your specific needs.

Request a Proposal